Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$90.91 - $112.75 $61 Million - $75.6 Million
-670,569 Reduced 91.28%
64,054 $6.76 Million
Q3 2023

Nov 09, 2023

SELL
$98.5 - $125.08 $128 Million - $162 Million
-1,295,659 Reduced 63.82%
734,623 $79.8 Million
Q2 2023

Aug 10, 2023

SELL
$102.58 - $129.66 $59.6 Million - $75.3 Million
-580,576 Reduced 22.24%
2,030,282 $219 Million
Q1 2023

May 11, 2023

BUY
$122.57 - $153.67 $25 Million - $31.4 Million
204,158 Added 8.48%
2,610,858 $325 Million
Q4 2022

Feb 10, 2023

BUY
$118.43 - $186.05 $21.1 Million - $33.1 Million
177,787 Added 7.98%
2,406,700 $362 Million
Q3 2022

Nov 10, 2022

BUY
$127.65 - $183.11 $190 Million - $272 Million
1,487,687 Added 200.71%
2,228,913 $301 Million
Q2 2022

Aug 12, 2022

BUY
$123.25 - $186.24 $39.6 Million - $59.9 Million
321,424 Added 76.57%
741,226 $111 Million
Q1 2022

May 13, 2022

BUY
$126.25 - $231.85 $151,878 - $278,915
1,203 Added 0.29%
419,802 $71.6 Million
Q4 2021

Feb 11, 2022

SELL
$216.64 - $362.52 $602,475 - $1.01 Million
-2,781 Reduced 0.66%
418,599 $108 Million
Q3 2021

Nov 12, 2021

SELL
$205.93 - $447.23 $75.1 Million - $163 Million
-364,760 Reduced 46.4%
421,380 $115 Million
Q2 2021

Aug 12, 2021

SELL
$113.32 - $241.49 $90.2 Million - $192 Million
-796,116 Reduced 50.32%
786,140 $176 Million
Q1 2021

May 11, 2021

BUY
$85.73 - $119.5 $13.3 Million - $18.6 Million
155,682 Added 10.91%
1,582,256 $173 Million
Q4 2020

Feb 10, 2021

SELL
$72.71 - $129.54 $25.7 Million - $45.7 Million
-353,119 Reduced 19.84%
1,426,574 $116 Million
Q3 2020

Nov 12, 2020

BUY
$57.81 - $104.17 $13.2 Million - $23.8 Million
228,415 Added 14.72%
1,779,693 $123 Million
Q2 2020

Aug 12, 2020

BUY
$38.58 - $66.74 $59.8 Million - $104 Million
1,551,278 New
1,551,278 $104 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $30B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Artisan Partners Limited Partnership Portfolio

Follow Artisan Partners Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Artisan Partners Limited Partnership with notifications on news.